Marwan Saad, PhD
Interventional Cardiology · Providence, RINPI 1881054328
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (37.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Edwards Lifesciences at 49.7% of the total. 2025 is the largest year on record at $23,796, more than ten times the $944 reported in 2019. Among interventional cardiology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $329.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$28K
- Medtronic$22K
- Abbott$4K
- Boston Scientific$2K
- Ancora Heart, Inc.$696
- Astellas Pharma US Inc$215
- plus $208 from 3 others
What the payments were for
- Consulting fees$18,25032%
- Grants$21,14037%
- Travel & lodging$9,78217%
- Food & beverage$7,58113%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 101 | $28,316 |
| Medtronic(2 entities) | 12 | $21,662 |
| Abbott | 39 | $3,771 |
| Boston Scientific | 11 | $2,083 |
| Ancora Heart, Inc. | 3 | $696 |
| Astellas Pharma US Inc | 3 | $215 |
| Teleflex LLC | 2 | $167 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$16,214
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,995
- MitraClip$1,600
- WATCHMAN Access System$1,500
- EVOQUE$1,329
- SAPIEN 3 Ultra RESILIA$1,314
- AccuCinch$696
- AMPLATZER$548
- AMPLATZER AMULET$337
- CoreValve Evolut$266
- COREVALVE EVOLUT R$155
- Epic$137
- GENERAL VASCULAR ACCESS$130
- MANTA$130
- MitraClip System$129
- CROSSBOSS$107
How this compares
$56,951 in reported general payments places this provider in the 90th percentile of 23 interventional cardiology providers in Rhode Island.
See all interventional cardiology providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $12,327 |
| ClopidogrelClopidogrel Bisulfate | 51 | $652 |
| Metoprolol Succinate | 14 | $173 |
| Furosemide | 18 | $138 |
| Spironolactone | 14 | $59 |
| Prednisone | 14 | $15 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Providence
- Peter SoukasProvidence$798K
- Jinnette AbbottProvidence$156K
- Hafiz ImranProvidence$18K
- Paul GordonProvidence$13K
- Omar HyderProvidence$9K
- Anum AsifProvidence$6K
- Ahmed ElkaryoniProvidence$3K
- Barry SharafProvidence$3K
- Mitchel SklarProvidence$2K
- Saraschandra VallabhajosyulaProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.